A new study suggests that the Alzheimer's drug candidates CMS121 and J147 may be useful for treating a broader array of conditions and points out a new pathway that links normal ageing to Alzheimer's disease.The research was published in the journal eLife.According to Pamela Maher, a senior staff scientist at Salk and a co-corresponding author of the new paper, "This study further validated these two compounds CMS121 and J147, not only as Alzheimer's drug candidates but also as potentially more widely useful for their anti-ageing effects,"Old age is the biggest risk factor for Alzheimer's disease -- above the age of 65, a person's risk of developing the disease doubles about every five years. However, at a molecular level, scientists aren't sure what occurs in the brain with ageing that contributes to Alzheimer's."The contribution of old age-associated detrimental processes to the disease has been largely neglected in Alzheimer's disease drug discovery," says Antonio Currais, a Salk ..
